Currently, there are 589.80M common shares owned by the public and among those 579.26M shares have been available to trade.
The company’s stock has a 5-day price change of 3.70% and 3.14% over the past three months. EW shares are trading -1.99% year to date (YTD), with the 12-month market performance down to -1.35% lower. It has a 12-month low price of $58.93 and touched a high of $96.12 over the same period. EW has an average intraday trading volume of 5.00 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.06%, 0.97%, and -4.39% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 86.37% of the company’s 589.80M shares outstanding.
It has a market capitalization of $42.80B and a beta (3y monthly) value of 1.10. The stock’s trailing 12-month PE ratio is 10.47, while the earnings-per-share (ttm) stands at $6.93. The company has a PEG of 3.49 and a Quick Ratio of 2.89 with the debt-to-equity ratio at 0.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.64% over the week and 2.24% over the month.
Earnings per share for the fiscal year are expected to increase by 2.31%, and -4.84% over the next financial year. EPS should shrink at an annualized rate of 3.00% over the next five years, compared to 15.35% over the past 5-year period.
Looking at the support for the EW, a number of firms have released research notes about the stock. Wolfe Research stated their Underperform rating for the stock in a research note on January 16, 2025, with the firm’s price target at $60. Morgan Stanley was of a view on October 11, 2024 that the stock is Equal-Weight, while Jefferies gave the stock Hold rating on September 18, 2024, issuing a price target of $85- $70. Daiwa Securities on their part issued Outperform rating on July 31, 2024.
